Welcome to our dedicated page for Kodiak Sciences SEC filings (Ticker: KOD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kodiak Sciences Inc. (Nasdaq: KOD) SEC filings, offering insight into how the precommercial retina-focused biotechnology company reports its activities to regulators. Kodiak Sciences develops biologic therapeutics for retinal vascular diseases and macular edema secondary to inflammation (MESI), and its filings reflect the progress and funding of these programs.
Investors can review Form 8-K current reports where Kodiak discloses material events, such as quarterly financial results and business highlights, or the terms and completion of public offerings of common stock. For example, a December 18, 2025 Form 8-K describes the underwriting agreement and closing of an 8,000,000-share public offering that generated gross proceeds of approximately $184 million before expenses.
Through its shelf registration statement on Form S-3 and related prospectus supplements, Kodiak outlines how it may issue securities to finance its late-stage clinical programs, including Phase 3 studies like GLOW2, DAYBREAK, PEAK and PINNACLE. Additional filings, such as quarterly and annual reports when available, typically provide more detail on research and development expenses, cash position and the status of clinical trials for tarcocimab, KSI-501 and KSI-101.
On Stock Titan, users can view Kodiak’s latest SEC submissions as they are posted to EDGAR and use AI-powered tools to summarize complex documents. These tools can help explain offering terms, highlight key clinical and financial disclosures, and surface information on topics such as capital raising, research spending and trial milestones relevant to KOD.
Kodiak Sciences Inc. Schedule 13G filed by Point72-related filers reports collective beneficial ownership of 2,908,836 shares of Kodiak Sciences common stock, representing 5.5% of the class as of the close of business on August 18, 2025. The filing attributes shared voting and shared dispositive power of all reported shares to Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen, with no sole voting or dispositive power reported. Point72 Associates holds the shares and Point72 Asset Management acts as investment manager; Point72 Capital Advisors is the general partner and Mr. Cohen controls the entities. The filers state the shares were not acquired to change or influence control of the issuer. A Joint Filing Agreement is filed as Exhibit 99.1.
Kodiak Sciences Inc. (KOD) reported continued clinical progress alongside significant cash burn and liquidity concerns. For the six months ended June 30, 2025 the company recorded a net loss of $111.8 million and used $63.8 million of cash in operations. The company reported $104.2 million of cash and cash equivalents as of June 30, 2025 (and $110.349 million including restricted cash), an accumulated deficit of $1,440,512 (amounts presented in thousands) and a $100,000 liability related to the sale of future royalties. Management states there is substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.
Operationally, Kodiak is advancing multiple late-stage programs. GLOW2 enrollment is complete (more than 250 patients) with topline data expected 1Q 2026; DAYBREAK (tarcocimab and KSI-501) remains actively enrolling with topline data expected 3Q 2026 and the company intends to seek a single BLA in 2026 following these results. KSI-101 completed Phase 1b APEX with selected doses moving into Phase 3 PEAK and PINNACLE, which are actively enrolling. The company recognized a $1.9 million non-cash lease impairment tied to a sublease and recorded sublease income in 2025. Research and development expense rose materially to $86.4 million for the six months ended June 30, 2025, reflecting expanded pivotal trials and manufacturing work.
Kodiak Sciences Inc. disclosed in a Form 8-K dated August 13, 2025 that it published a press release reporting the company’s financial results for the quarter ended June 30, 2025 and related business highlights; that press release is attached as Exhibit 99.1 to this report.
The filing states the press release and information contained or incorporated herein shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by specific reference. The 8-K lists an Inline XBRL cover page as Exhibit 104 and is signed by Victor Perlroth, M.D., Chief Executive Officer. The company’s common stock trades under the ticker KOD on The Nasdaq Stock Market.